Try our Advanced Search for more refined results
Life Sciences
- 
									September 30, 2025
									McKinsey Trims Endo Suit But Can't Nix Indemnification ClaimA New York bankruptcy judge trimmed an adversary suit Monday claiming McKinsey & Co. Inc. should pay at least $1.5 billion to cover costs bankrupt pharmaceutical developer Endo International racked up defending against opioid claims, tossing nearly all allegations with leave to amend, but greenlighting an indemnification claim. 
- 
									September 30, 2025
									3rd Circ. Parses 'Could' And 'Would' In Lipitor LawsuitA Third Circuit panel questioned Tuesday whether drug wholesalers and health plans had offered enough evidence that Pfizer Inc. and Ranbaxy Laboratories Ltd. conspired to delay generic competition for the cholesterol drug Lipitor, focusing on whether the U.S. Food and Drug Administration would have approved the competitor earlier than November 2011. 
- 
									September 30, 2025
									Biogen Told To Pay Genentech $88M After IP Royalties MistrialBiogen MA Inc. owes Genentech Inc. more than $88 million in royalties related to expired patents, a California federal judge ruled Tuesday in a rare post-mistrial verdict arrangement. 
- 
									September 30, 2025
									4 Federal Circuit Clashes To Watch In OctoberThe Federal Circuit will hear arguments next week in cases where a nearly $42 million patent win for Seagen hangs in the balance due to a later post-grant review invalidity decision and where Regenxbio is seeking to undo the invalidation of its gene therapy patent for covering a natural product. 
- 
									September 30, 2025
									Blue Cross Insurers Sanctioned For 2-Year Discovery DrawoutAn Illinois federal judge has ordered a host of Blue Cross and Blue Shield insurers to pay the fees and costs Walgreens incurred in an overbilling suit while helping to work through discovery production, which took two years to remediate with a special master. 
- 
									September 30, 2025
									HHS Moves To Suspend Harvard From FundingThe civil rights office at the U.S. Department of Health and Human Services is moving to cut off Harvard University from future funding, a maneuver legal experts say could stymie healthcare and biomedical research. 
- 
									September 30, 2025
									Judge Freezes Chinese Cos.' Assets In X-Ray IP SuitTwo Chinese companies were barred from doing business in the United States and had their U.S.-based assets frozen by a Chicago federal judge until they comply with an earlier injunction order, with the judge stopping short of referring the pair and two of their executives for criminal contempt charges. 
- 
									September 30, 2025
									Hospital Urges Justices To Review 7th Circ. Medicaid RulingA Chicago hospital urged the U.S. Supreme Court to take up its petition for review of a Seventh Circuit ruling that had shut down its suit against the state of Illinois seeking enforcement of timely Medicaid payments, saying it's an "excellent opportunity" to address "resulting uncertainties" after a recent ruling against Planned Parenthood. 
- 
									September 30, 2025
									Pharma Co. Asks Judge To Toss 'Vague' Investor Class ActionCounsel for Marinus Pharmaceuticals Inc. told a Pennsylvania federal judge Tuesday that a shareholder class action alleging the company misled investors about the potential success of an epilepsy drug was based solely on "vague and uncorroborated" statements from confidential witnesses. 
- 
									September 29, 2025
									Supreme Court Considers 7 Patent PetitionsThe U.S. Supreme Court held its first conference Monday, presenting the justices with several petitions of interest to patent practitioners before the court's new term kicks off next week. 
- 
									September 29, 2025
									Pfizer Says Drugmaker Moving Too Early On Arthritis GenericPfizer has asked a Delaware federal court to block generic-drug maker Prinston Pharmaceutical from moving forward with plans to sell a generic version of the arthritis drug Xeljanz that would allegedly infringe Pfizer's patent. 
- 
									September 29, 2025
									Tribe Drops Price-Fixing Suit Against Drugmakers, PBMsThe Miccosukee Tribe in Florida has dropped its lawsuit alleging drugmakers and pharmacy benefit managers Eli Lilly, Express Scripts, CVS Health and other companies illegally conspired to limit competition and artificially inflate the price of insulin drugs, according to a notice of voluntary dismissal. 
- 
									September 29, 2025
									Honeywell Says Ex-GC's Age Bias Suit Belongs Only In ChinaA former vice president and general counsel for a Honeywell International Inc. subsidiary is seeking a redo for her age discrimination claims despite the fact that her employment contracts say those claims must be litigated in China, Honeywell told a North Carolina federal court Friday. 
- 
									September 29, 2025
									CTA Could Face Second Ill. Jury Over Vaccine Bias AllegationsAn Illinois federal judge has found there are too many open questions to give a win to the Chicago Transit Authority in a former employee's suit over its decision to terminate him after he sought a religious exemption to the agency's mandatory COVID-19 vaccination policy. 
- 
									September 29, 2025
									House GOP Lawmakers Back ITC Import Ban Won By OuraA group of House Republicans want the U.S. Trade Representative to uphold the U.S. International Trade Commission's decision to block Ultrahuman and RingConn from importing products it held infringed an Ouraring Inc. wearable computing device patent. 
- 
									September 29, 2025
									No New Trial In Eyedrop TM Case, But Damages Cut To $11MA California federal judge has rejected a motion for a new trial in a trademark case between eyedrop makers after a jury awarded one side $35 million, saying there was plenty of evidence to support a finding of infringement while reducing the damages award to about $11.2 million. 
- 
									September 29, 2025
									6th Circ. Won't Revive Software Development IP CaseThe Sixth Circuit has declined to revive copyright infringement and trade secrets claims brought by a business communications company over a software development tool, saying the company waited too long to look into its concerns that a rival was distributing a modified version of the software. 
- 
									September 29, 2025
									Terumo Secures $5M Cost Award After Beating Cancer ClaimsA Colorado state judge has granted a healthcare company over $5 million in costs following the company's win in its first bellwether trial against Lakewood residents who claim its medical sterilization facility caused their cancer. 
- 
									September 29, 2025
									Catching Up With Delaware's Chancery CourtA Delaware vice chancellor expressed disappointment and concern over what she says is a "breakdown" in "civility and respect" that has emerged in recent Delaware corporate litigation. A $30 million settlement was approved in the five-year running Match.com reverse spinoff suit, and the top brass of Estée Lauder were hit with a derivative suit for allegedly covering up the company's reliance on prohibited, duty-free "gray market" sales of its products in China. 
- 
									September 26, 2025
									Stewart Keeps Discretion Duty As Squires Takes On RPIs, AIIn John Squires' first week as U.S. Patent and Trademark Office director, he walked back precedent from the first Trump administration, claimed machine learning should be patent-eligible, and designated Deputy Director Coke Morgan Stewart to continue handling discretionary denial reviews. 
- 
									September 26, 2025
									Semler Scientific, Bard To Pay $37M To End FCA ClaimsThe Department of Justice announced on Friday that two companies have agreed to pay nearly $37 million to resolve claims that they knowingly recommended healthcare providers submit erroneous Medicare claims for tests for diagnosing artery disease. 
- 
									September 26, 2025
									Judge Criticizes Push For Harsher Sentence In CytoDyn CaseA Maryland judge on Friday blasted federal prosecutors for seeking an enhanced sentence for a former biotech executive convicted of fraud for his role in the CytoDyn stock inflation scheme, saying the government wanted a harsher sentence for allegations he was already acquitted of at trial. 
- 
									September 26, 2025
									CareDx Asks 3rd Circ. To Rethink $45M False Ad CaseMedical testing company CareDx has asked the Third Circuit for a panel rehearing or a rehearing before the entire circuit to consider reinstating a $45 million jury award in a false advertisement case over genetic testing technology against rival Natera. 
- 
									September 26, 2025
									Inotiv Inks $8.75M Investor Deal Over Animal Welfare ClaimsMedical research services provider Inotiv Inc. and its shareholders asked an Indiana federal court to approve an $8.75 million settlement to resolve investors' claims the company concealed that its subsidiaries were under investigation by the U.S. Department of Justice for animal welfare and smuggling violations. 
- 
									September 26, 2025
									Bayer Investors Seek Final OK Of $38M Settlement, Atty FeesBayer AG shareholders have asked a California federal judge to give final approval of its $38 million settlement with the German multinational to end claims it downplayed litigation risks related to the weedkiller Roundup, saying the deal, which seeks over $10 million in attorney fees, is fair. 
Expert Analysis
- 
								
								How The Healthline Privacy Settlement Redefines Ad Tech Use  The Healthline settlement is the first time California has drawn a clear line in the sand around how website tracking must function in practice, so if your site uses tracking technologies, especially around sensitive content like health or finance, regulators are inspecting your website's back end, not just its banner, say attorneys at Baker Donelson. 
- 
								
								How Sweeping Budget Bill Shakes Up Health Industry  With the recently passed One Big Beautiful Bill Act marking one of the most significant overhauls of federal health policy since the passage of the Affordable Care Act, providers, managed care organizations and life sciences companies must now shift focus from policy review to implementation planning, say advisers at Holland & Knight. 
- 
								Series Adapting To Private Practice: From ATF Director To BigLaw  As a two-time boomerang partner, returning to BigLaw after stints as a U.S. attorney and the director of the Bureau of Alcohol, Tobacco, Firearms and Explosives, people ask me how I know when to move on, but there’s no single answer — just clearly set your priorities, says Steven Dettelbach at BakerHostetler. 
- 
								
								A Look At Key 5th Circ. White Collar Rulings So Far This Year  In the first half of 2025, the Fifth Circuit has decided numerous cases of particular import to white collar practitioners, which collectively underscore the critical importance of meticulous recordbuilding, procedural compliance and strategic litigation choices at every stage of a case, says Joe Magliolo at Jackson Walker. 
- 
								
								High Court Cert Spotlights Varying Tests For Federal Removal  A recent decision by the U.S. Supreme Court to review Chevron v. Plaquemines Parish, a case involving the federal officer removal statute, highlights three other recent circuit court decisions raising federal removal questions, and serves as a reminder that defendants are the masters of removal actions, says Varun Aery at Hollingsworth. 
- 
								
								How To Increase 3rd-Party Preissuance Patent Submissions-(1).jpg)  Attorneys Marian Underweiser and Marc Ehrlich, who helped draft the America Invents Act, discuss changes that the U.S. Patent and Trademark Office could potentially implement to facilitate its hopes for increased participation in front-end patent challenges. 
- 
								
								Trump Air Emissions Carveouts Cloud The Regulatory Picture  President Donald Trump's new proclamations temporarily exempting key U.S. industries from air toxics standards, issued under a narrow, rarely-used provision of the Clean Air Act, will likely lead to legal challenges and tighter standards in some states, contributing to further regulatory uncertainty, say attorneys at GableGotwals. 
- 
								Series Playing Baseball Makes Me A Better Lawyer  Playing baseball in college, and now Wiffle ball in a local league, has taught me that teamwork, mental endurance and emotional intelligence are not only important to success in the sport, but also to success as a trial attorney, says Kevan Dorsey at Swift Currie. 
- 
								
								What US Medicine Onshoring Means For Indian Life Sciences  Despite the Trump administration's latest moves to onshore essential medicine manufacturing, India will likely remain an indispensable component of the U.S. drug supply chain, but Indian manufacturers should prepare for stricter compliance checks, says Jashaswi Ghosh at Holon Law Partners. 
- 
								Series Law School's Missed Lessons: Skillful Persuasion  In many ways, law school teaches us how to argue, but when the ultimate goal is to get your client what they want, being persuasive through preparation and humility is the more likely key to success, says Michael Friedland at Friedland Cianfrani. 
- 
								
								FCA Working Group Reboot Signals EHR Compliance Risk  The revival of the False Claims Act working group is an aggressive expansion of enforcement efforts by the Justice Department and the U.S. Department of Health and Human Services targeted toward technology-enabled fraud involving electronic health records and other data, say attorneys at ArentFox Schiff. 
- 
								
								Litigation Inspiration: How To Respond After A Loss  Every litigator loses a case now and then, and the sting of that loss can become a medicine that strengthens or a poison that corrodes, depending on how the attorney responds, says Bennett Rawicki at Hilgers Graben. 
- 
								
								While On Firmer Ground, Uncertainty Remains For SEC's ALJs  The U.S. District Court for the District of Columbia's recent opinion in Lemelson v. U.S. Securities and Exchange Commission affirmed the legitimacy of the SEC's administrative proceedings, but pointedly left unanswered the constitutional merits of tenure protection enjoyed by SEC administrative law judges — potentially the subject of future U.S. Supreme Court review, says Dean Conway at Carlton Fields. 
- 
								
								FDA's Hasty Policymaking Approach Faces APA Challenges  Though the U.S. Food and Drug Administration has abandoned its usual notice-and-comment process for implementing new regulatory initiatives, two recent district court decisions make clear that these programs are still susceptible to Administrative Procedure Act challenges, says Rachel Turow at Skadden. 
- 
								
								Legal Considerations Around Ibogaine As Addiction Therapy  Recent funding approval in Texas pertaining to the use of ibogaine for the potential treatment of substance use disorders signals a growing openness to innovative addiction treatments, but also underscores the need for rigorous compliance with state and federal requirements and ethical research standards, say attorneys at Husch Blackwell.